Lataa...
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT pr...
Tallennettuna:
| Julkaisussa: | Oncotarget |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals LLC
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4914352/ https://ncbi.nlm.nih.gov/pubmed/26334099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.4801 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|